Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 5 (March 1), 2004: pp. 909-918
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.08.185
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Atkins, M. B.
Right arrow Articles by Sherman, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atkins, M. B.
Right arrow Articles by Sherman, M. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler, Theodore F. Logan, Janice P. Dutcher, Gary R. Hudes, Young Park, Song-Heng Liou, Bonnie Marshall, Joseph P. Boni, Gary Dukart, Matthew L. Sherman

From the Beth Israel Deaconess Medical Center, Boston, MA; University of Texas Health Science Center at San Antonio, San Antonio, TX; University of Chicago, Chicago, IL; Indiana University, Indianapolis, IN; Our Lady of Mercy Cancer Center, NY Medical College, Bronx, NY; Fox Chase Cancer Center, Philadelphia, PA; and Wyeth Research, Cambridge, MA, and Collegeville, PA.

Address reprint requests to Michael Atkins, MD, Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, E Campus, Kirstein 158, Boston, MA 02215; e-mail: matkins{at}bidmc.harvard.edu

PURPOSE: To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC).

PATIENTS AND METHODS: Patients (n = 111) were randomly assigned to receive 25, 75, or 250 mg CCI-779 weekly as a 30-minute intravenous infusion. Patients were evaluated for tumor response, time to tumor progression, survival, and adverse events. Blood samples were collected to determine CCI-779 pharmacokinetics.

RESULTS: CCI-779 produced an objective response rate of 7% (one complete response and seven partial responses) and minor responses in 26% of these advanced RCC patients. Median time to tumor progression was 5.8 months and median survival was 15.0 months. The most frequently occurring CCI-779–related adverse events of all grades were maculopapular rash (76%), mucositis (70%), asthenia (50%), and nausea (43%). The most frequently occurring grade 3 or 4 adverse events were hyperglycemia (17%), hypophosphatemia (13%), anemia (9%), and hypertriglyceridemia (6%). Neither toxicity nor efficacy was significantly influenced by CCI-779 dose level. Patients were retrospectively classified into good-, intermediate-, or poor-risk groups on the basis of criteria used by Motzer et al for a first-line metastatic RCC population treated with interferon alfa. Within each risk group, the median survivals of patients at each dose level were similar.

CONCLUSION: In patients with advanced RCC, CCI-779 showed antitumor activity and encouraging survival and was generally well tolerated over the three dose levels tested.

Supported by research funding from Wyeth Research, Collegeville, PA.

Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002, and the 39th Annual Meeting, Chicago, IL, May 31-June 1, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. S. Hong, S. M. Sebti, R. A. Newman, M. A. Blaskovich, L. Ye, R. F. Gagel, S. Moulder, J. J. Wheler, A. Naing, N. M. Tannir, et al.
Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
Clin. Cancer Res., November 15, 2009; 15(22): 7061 - 7068.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
T. B. Dorff, A. Goldkorn, and D. I. Quinn
Review: Targeted therapy in renal cancer
Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205.
[Abstract] [PDF]

Home page
 Ann OncolHome page
S. Stacchiotti, A. Marrari, E. Tamborini, E. Palassini, E. Virdis, A. Messina, F. Crippa, C. Morosi, A. Gronchi, S. Pilotti, et al.
Response to imatinib plus sirolimus in advanced chordoma
Ann. Onc., November 1, 2009; 20(11): 1886 - 1894.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. J. Cersosimo
Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2
Am. J. Health Syst. Pharm., September 15, 2009; 66(18): 1625 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. S. Fung, L. Wu, and I. F. Tannock
Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts
Clin. Cancer Res., September 1, 2009; 15(17): 5389 - 5395.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, C. Gisselbrecht, A. Laurell, F. Offner, A. Strahs, A. Berkenblit, et al.
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol., August 10, 2009; 27(23): 3822 - 3829.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Schwaab, A. Schwarzer, B. Wolf, T. S. Crocenzi, J. D. Seigne, N. A. Crosby, B. F. Cole, J. L. Fisher, J. C. Uhlenhake, D. Mellinger, et al.
Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a Therapy in Metastatic Renal Cell Carcinoma Patients
Clin. Cancer Res., August 1, 2009; 15(15): 4986 - 4992.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini
Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient
J. Clin. Oncol., July 1, 2009; 27(19): 3225 - 3234.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. K. Anagnostou, G. Bepler, K. N. Syrigos, L. Tanoue, S. Gettinger, R. J. Homer, D. Boffa, F. Detterbeck, and D. L. Rimm
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Clin. Cancer Res., June 15, 2009; 15(12): 4157 - 4164.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Herberger, W. Berger, H. Puhalla, K. Schmid, S. Novak, A. Brandstetter, C. Pirker, T. Gruenberger, and M. Filipits
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells
Mol. Cancer Ther., June 1, 2009; 8(6): 1547 - 1556.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Meric-Bernstam and A. M. Gonzalez-Angulo
Targeting the mTOR Signaling Network for Cancer Therapy
J. Clin. Oncol., May 1, 2009; 27(13): 2278 - 2287.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. N. Sternberg
Expanding the boundaries of clinical practice: building on experience with targeted therapies
Ann. Onc., May 1, 2009; 20(suppl_1): i1 - i6.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ravaud
How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents
Ann. Onc., May 1, 2009; 20(suppl_1): i7 - i12.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Hartford, A. A. Desai, L. Janisch, T. Karrison, V. M. Rivera, L. Berk, J. W. Loewy, H. Kindler, W. M. Stadler, H. L. Knowles, et al.
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Clin. Cancer Res., February 15, 2009; 15(4): 1428 - 1434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Kim, E. Jonasch, A. Alexander, J. D. Short, S. Cai, S. Wen, D. Tsavachidou, P. Tamboli, B. A. Czerniak, K. A. Do, et al.
Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
Clin. Cancer Res., January 1, 2009; 15(1): 81 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M.-C. Crouthamel, J. A. Kahana, S. Korenchuk, S.-Y. Zhang, G. Sundaresan, D. J. Eberwein, K. K. Brown, and R. Kumar
Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
Clin. Cancer Res., January 1, 2009; 15(1): 217 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
J. Brugarolas
Molecular Pathways and Targeted Therapies for Renal Cell Carcinoma
ASCO Educational Book, January 1, 2009; 2009(1): 710 - 715.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Lunardi, M. O. Vannozzi, A. Armirotti, M. Nicodemo, M. Venturini, and L. Cavallini
Temsirolimus in Patients With Renal Cancer on Hemodialysis
J. Clin. Oncol., December 1, 2008; 26(34): 5652 - 5653.
[Full Text] [PDF]

Home page
 JCOHome page
J. Brugarolas
In Reply
J. Clin. Oncol., December 1, 2008; 26(34): 5653 - 5654.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Oncologist, October 1, 2008; 13(10): 1084 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bellmunt, C. Szczylik, J. Feingold, A. Strahs, and A. Berkenblit
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
Ann. Onc., August 1, 2008; 19(8): 1387 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Negrier
Temsirolimus in metastatic renal cell carcinoma
Ann. Onc., August 1, 2008; 19(8): 1369 - 1370.
[Full Text] [PDF]

Home page
 JCOHome page
I. E. Haines
Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective
J. Clin. Oncol., July 20, 2008; 26(21): 3650 - 3652.
[Full Text] [PDF]

Home page
 JCOHome page
J. Brugarolas, Y. Lotan, L. Watumull, and W. Kabbani
Sirolimus in Metatastic Renal Cell Carcinoma
J. Clin. Oncol., July 10, 2008; 26(20): 3457 - 3460.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Garcia and D. Danielpour
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Mol. Cancer Ther., June 1, 2008; 7(6): 1347 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M.W. Verheul, B. Salumbides, K. Van Erp, H. Hammers, D. Z. Qian, T. Sanni, P. Atadja, and R. Pili
Combination Strategy Targeting the Hypoxia Inducible Factor-1{alpha} with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors
Clin. Cancer Res., June 1, 2008; 14(11): 3589 - 3597.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Shor, W.-G. Zhang, L. Toral-Barza, J. Lucas, R. T. Abraham, J. J. Gibbons, and K. Yu
A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
Cancer Res., April 15, 2008; 68(8): 2934 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
P. J Houghton, J. B Easton, and R. T Kurmasheva
mTOR as a Target for Cancer Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 111 - 120.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Sleijfer and E. Wiemer
Dose Selection in Phase I Studies: Why We Should Always Go for the Top
J. Clin. Oncol., April 1, 2008; 26(10): 1576 - 1578.
[Full Text] [PDF]

Home page
 JCOHome page
R. H. El-Maraghi and E. A. Eisenhauer
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
J. Clin. Oncol., March 10, 2008; 26(8): 1346 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. P. Steensma
Is Anemia of Cancer Different From Chemotherapy-Induced Anemia?
J. Clin. Oncol., March 1, 2008; 26(7): 1022 - 1024.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
Clin. Cancer Res., March 1, 2008; 14(5): 1286 - 1290.
[Full Text] [PDF]

Home page
 BloodHome page
M. Marzec, X. Liu, M. Kasprzycka, A. Witkiewicz, P. N. Raghunath, M. El-Salem, E. Robertson, N. Odum, and M. A. Wasik
IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes
Blood, February 15, 2008; 111(4): 2181 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. Vahid and P. E. Marik
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors*
Chest, February 1, 2008; 133(2): 528 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
W. Feng, R. E. Brown, C. D. Trung, W. Li, L. Wang, T. Khoury, S. Alrawi, J. Yao, K. Xia, and D. Tan
Morphoproteomic Profile of mTOR, Ras/Raf Kinase/ERK, and NF-{kappa}B Pathways in Human Gastric Adenocarcinoma
Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 195 - 209.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Kuhn, S. M. Chang, P. Y. Wen, T. F. Cloughesy, H. Greenberg, D. Schiff, C. Conrad, K. L. Fink, H. I. Robins, M. Mehta, et al.
Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma
Clin. Cancer Res., December 15, 2007; 13(24): 7401 - 7406.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. J. Costa and H. A. Drabkin
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Oncologist, December 1, 2007; 12(12): 1404 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Ebbinghaus, M. Hussain, N. Tannir, M. Gordon, A. A. Desai, R. A. Knight, R. A. Humerickhouse, J. Qian, G. B. Gordon, and R. Figlin
Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Clin. Cancer Res., November 15, 2007; 13(22): 6689 - 6695.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. Boni, C. Leister, J. Burns, M. Cincotta, B. Hug, and L. Moore
Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450-Inducing Medications
J. Clin. Pharmacol., November 1, 2007; 47(11): 1430 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, et al.
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Blood, November 1, 2007; 110(9): 3374 - 3383.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, G. R. Hudes, B. D. Curti, D. F. McDermott, B. J. Escudier, S. Negrier, B. Duclos, L. Moore, T. O'Toole, J. P. Boni, et al.
Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma
J. Clin. Oncol., September 1, 2007; 25(25): 3958 - 3964.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Herberger, H. Puhalla, M. Lehnert, F. Wrba, S. Novak, A. Brandstetter, B. Gruenberger, T. Gruenberger, R. Pirker, and M. Filipits
Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma
Clin. Cancer Res., August 15, 2007; 13(16): 4795 - 4799.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
X. Wan and L. J. Helman
The Biology Behind mTOR Inhibition in Sarcoma
Oncologist, August 1, 2007; 12(8): 1007 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Martin and R. Schilder
Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition
J. Clin. Oncol., July 10, 2007; 25(20): 2894 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Chan, A. P. Weng, R. Tibshirani, J. C. Aster, and P. J. Utz
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia
Blood, July 1, 2007; 110(1): 278 - 286.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. L. Phung, G. Eyiah-Mensah, R. K. O'Donnell, R. Bieniek, S. Shechter, K. Walsh, C. Kuperwasser, and L. E. Benjamin
Endothelial Akt Signaling Is Rate-Limiting for Rapamycin Inhibition of Mouse Mammary Tumor Progression
Cancer Res., June 1, 2007; 67(11): 5070 - 5075.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, et al.
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
N. Engl. J. Med., May 31, 2007; 356(22): 2271 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Atkins, M. S. Ernstoff, R. A. Figlin, K. T. Flaherty, D. J. George, W. G. Kaelin Jr., E. D. Kwon, T. A. Libermann, W. M. Linehan, D. F. McDermott, et al.
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
Clin. Cancer Res., January 15, 2007; 13(2): 667s - 670s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Ernstoff, T. S. Crocenzi, J. D. Seigne, N. A. Crosby, B. F. Cole, J. L. Fisher, J. C. Uhlenhake, D. Mellinger, C. Foster, C. J. Farnham, et al.
Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang
Clin. Cancer Res., January 15, 2007; 13(2): 733s - 740s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Cho, S. Signoretti, M. Regan, J. W. Mier, and M. B. Atkins
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 758s - 763s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. H. Patel, R. S.V. Chadalavada, R.S.K. Chaganti, and R. J. Motzer
Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma
Clin. Cancer Res., December 15, 2006; 12(24): 7215 - 7220.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer and R. M. Bukowski
Targeted Therapy for Metastatic Renal Cell Carcinoma
J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, E. Brown, F. Petti, S. McCormack, J. D. Haley, K. K. Iwata, N. W. Gibson, and G. Griffin
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Mol. Cancer Ther., November 1, 2006; 5(11): 2676 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer.
Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. W.L. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi, A. Ferrajoli, D. Thomas, W. Wierda, E. Apostolidou, M. Albitar, et al.
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res., September 1, 2006; 12(17): 5165 - 5173.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Ann. Onc., August 1, 2006; 17(8): 1185 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Di Paolo, A. Teutonico, D. Leogrande, C. Capobianco, and P. F. Schena
Chronic Inhibition of Mammalian Target of Rapamycin Signaling Downregulates Insulin Receptor Substrates 1 and 2 and AKT Activation: A Crossroad between Cancer and Diabetes?
J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2236 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Powis, N. Ihle, and D. L. Kirkpatrick
Practicalities of drugging the phosphatidylinositol-3-kinase/akt cell survival signaling pathway.
Clin. Cancer Res., May 15, 2006; 12(10): 2964 - 2966.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. T. Teachey, D. A. Obzut, J. Cooperman, J. Fang, M. Carroll, J. K. Choi, P. J. Houghton, V. I. Brown, and S. A. Grupp
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
Blood, February 1, 2006; 107(3): 1149 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
F. Lin, P. L. Zhang, X. J. Yang, J. W. Prichard, M. Lun, and R. E. Brown
Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated mTOR Pathway in Renal Cell Carcinomas
Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 283 - 293.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. T. Cohen and F. J. McGovern
Renal-Cell Carcinoma
N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490.
[Full Text] [PDF]

Home page
 JCOHome page
S. Chan, M. E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, et al.
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
J. Clin. Oncol., August 10, 2005; 23(23): 5314 - 5322.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, S. M. Geyer, I. Ghobrial, D. J. Inwards, R. Fonseca, P. Kurtin, S. M. Ansell, R. Luyun, P. J. Flynn, R. F. Morton, et al.
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
J. Clin. Oncol., August 10, 2005; 23(23): 5347 - 5356.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, et al.
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
J. Clin. Oncol., August 10, 2005; 23(23): 5294 - 5304.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Cohen, R. B. Cohen, and N. J. Meropol
Targeting Signal Transduction Pathways in Colorectal Cancer--More Than Skin Deep
J. Clin. Oncol., August 10, 2005; 23(23): 5374 - 5385.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. S. Zaltzman, R. Prasad, K. Chun, and S. Jothy
Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1748 - 1751.
[Full Text] [PDF]

Home page
 BloodHome page
P. S. Hammerman, C. J. Fox, M. J. Birnbaum, and C. B. Thompson
Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival
Blood, June 1, 2005; 105(11): 4477 - 4483.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. I. Feldman, J. M. Wu, M. A. Polokoff, M. J. Kochanny, H. Dinter, D. Zhu, S. L. Biroc, B. Alicke, J. Bryant, S. Yuan, et al.
Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1
J. Biol. Chem., May 20, 2005; 280(20): 19867 - 19874.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Atkins, M. Regan, D. McDermott, J. Mier, E. Stanbridge, A. Youmans, P. Febbo, M. Upton, M. Lechpammer, and S. Signoretti
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3714 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
I. M. Ghobrial, T. E. Witzig, and A. A. Adjei
Targeting Apoptosis Pathways in Cancer Therapy
CA Cancer J Clin, May 1, 2005; 55(3): 178 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Takeuchi, Y. Kondo, K. Fujiwara, T. Kanzawa, H. Aoki, G. B. Mills, and S. Kondo
Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibitors
Cancer Res., April 15, 2005; 65(8): 3336 - 3346.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Wu, D. C. Birle, and I. F. Tannock
Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts
Cancer Res., April 1, 2005; 65(7): 2825 - 2831.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Vignot, S. Faivre, D. Aguirre, and E. Raymond
mTOR-targeted therapy of cancer with rapamycin derivatives
Ann. Onc., April 1, 2005; 16(4): 525 - 537.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Recher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V. M.-D. Mas, D. Benzaquen, G. Laurent, F. Huguet, and B. Payrastre
Antileukemic activity of rapamycin in acute myeloid leukemia
Blood, March 15, 2005; 105(6): 2527 - 2534.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Burczynski, N. C. Twine, G. Dukart, B. Marshall, M. Hidalgo, W. M. Stadler, T. Logan, J. Dutcher, G. Hudes, W. L. Trepicchio, et al.
Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma
Clin. Cancer Res., February 1, 2005; 11(3): 1181 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Blood, December 15, 2004; 104(13): 4188 - 4193.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Dutcher
Mammalian Target of Rapamycin Inhibition
Clin. Cancer Res., September 15, 2004; 10(18): 6382S - 6387S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Hidalgo
New Target, New Drug, Old Paradigm
J. Clin. Oncol., June 15, 2004; 22(12): 2270 - 2272.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online